Cytogenetic and molecular associations with outcomes in HR-MDS treated with hypomethylating agents plus venetoclax

CONCLUSIONS: Knowledge of cytogenetic and molecular alterations may help identify which patients with HR-MDS benefit the most from venetoclax.PMID:38300723 | DOI:10.1158/1078-0432.CCR-23-2860

Source: Clinical Cancer Research - February 1, 2024 Category: Cancer & Oncology Authors: Alexandre Bazinet Sai Prasad Desikan Ziyi Li Juan Jose Rodriguez-Sevilla Sangeetha Venugopal Samuel Urrutia Guillermo Montalban-Bravo Koji Sasaki Kelly S Chien Danielle Hammond Rashmi Kanagal-Shamanna Irene Ganan-Gomez Tapan M Kadia Gautam Borthakur Court Source Type: research